Multicenter Phase II Study of Peritransplantation Immunosuppression Using ATG, Rituximab, Sirolimus and Mycophenolate Mofetil in Patient Receiving Mismatched Hematopoietic Cell Transplantation After Reduced Intensity Conditioning With Fludarabine and Treosulfan
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Antithymocyte globulin; Fludarabine; Mycophenolate mofetil; Rituximab; Sirolimus; Treosulfan
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Graft-versus-host disease; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 08 May 2018 Biomarkers information updated
- 26 May 2012 New source identified and integrated (European Clinical Trials Database: EudraCT2011-002192-41).
- 27 Apr 2012 New trial record